A New Federal Pathway for Homeopathy:
Senate Bill 4692 Introduced to Protect American Access to Homeopathic Medicine

Senators Tommy Tuberville (R-AL) and Mike Lee (R-UT) Introduce the Homeopathic Drug Product Safety, Quality, and Transparency Act

Overview

On June 4, 2026, U.S. Senator Tommy Tuberville (R-AL) introduced Senate Bill 4692, formally titled the Homeopathic Drug Product Safety, Quality, and Transparency Act. The bill is co-sponsored by Senator Mike Lee (R-UT) and has been referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP). It is the Senate companion to H.R. 7050, introduced earlier in 2026 by Representative Pete Sessions in the House.

For the millions of Americans who rely on homeopathic medicines as part of their personal healthcare, and for the practitioners and manufacturers who serve them, S.4692 represents the most significant legislative effort in decades to restore regulatory clarity, protect consumer access, and recognize homeopathy as a distinct and legitimate category of medicine under federal law.

Why This Bill Matters: The Regulatory Background

The U.S. Food and Drug Administration (FDA) first recognized homeopathic medicines under the Federal Food, Drug, and Cosmetic Act of 1938, and regulated them as a distinct class of products for the next eighty years. In 2019, however, the FDA abruptly withdrew its longstanding guidance (Compliance Policy Guide 400.400), leaving the homeopathic industry — and the consumers who rely on it — in a state of regulatory uncertainty. A subsequent 2022 FDA guidance imposed significant new restrictions on the lawful sale of homeopathic drug products, treating them under a framework designed for conventional pharmaceuticals.

The result has been years of confusion: homeopathic medicines that have been safely used for generations have faced the threat of being pulled from the market not because of any safety concerns, but because they were being evaluated against criteria designed for a fundamentally different category of drugs.

S.4692 is intended to correct that mismatch.

Key Provisions of S.4692

According to the official summary released by Senator Lee’s office, the Homeopathic Drug Product Safety, Quality, and Transparency Act would:

• Federally recognize homeopathic drug products as distinct from other pharmaceutical products, requiring their own independent regulatory framework.
• Establish a standard statutory definition of “homeopathic drug product” and clarify that such products are not “new drugs” under the Federal Food, Drug, and Cosmetic Act.
• Exempt homeopathic drug products from the traditional premarket approval process under Section 505 of the Federal Food, Drug, and Cosmetic Act — the process designed for conventional pharmaceuticals.
• Create a separate regulatory pathway for the FDA to oversee safety and quality standards tailored specifically to homeopathy.
• Exempt finished homeopathic drug products from required laboratory tests that measure the strength of each active ingredient — testing that is impractical and inappropriate for homeopathic dilutions.
• Permit homeopathy-appropriate labeling, including descriptions and dosage units consistent with traditional homeopathic practice, and clarify that claims made in compliance with the Act shall not be deemed false advertising.
• Establish a Homeopathic Drug Product Advisory Committee to consult with the Secretary of Health and Human Services on safety, quality, labeling, and regulatory approaches. The committee will include representatives from both consumer and practitioner backgrounds.
• Require the FDA to issue final Current Good Manufacturing Practice (CGMP) regulations tailored to homeopathic products within three years of enactment.
• Deem any non-homeopathic drug or supplement that uses the word “homeopathy” in its labeling as misbranded, protecting consumers from deceptive marketing.
• Apply federal serious-adverse-event reporting standards for nonprescription drugs to homeopathic drug products.
• Clarify that homeopathic drug products are not classified as biosimilars.
• Withdraw the FDA’s restrictive 2022 guidance on homeopathic drug products.
• Preserve state authority over the practice of homeopathy, leaving state homeopathic licensure and practice laws untouched.

Taken together, these provisions would replace today’s regulatory limbo with a clear, predictable, and homeopathy-appropriate federal framework.

What the Sponsors Are Saying

In introducing the bill, Senator Tuberville emphasized that he has long been a supporter of homeopathic medicine and believes Americans deserve access to safe, affordable, natural alternatives. He noted that the FDA should have a meaningful pathway to review and approve homeopathic remedies rather than leaving them in regulatory uncertainty.

Senator Lee framed the legislation as a matter of healthcare freedom, arguing that the current federal framework — built around conventional pharmaceuticals — is poorly suited to evaluate homeopathic products. He said the bill responds to thousands of American families who have asked Washington for a better approach.

Broad Coalition of Endorsements

S.4692 has been endorsed by a wide coalition of consumer, health-freedom, and industry organizations, including:

• Americans for Homeopathy Choice Action
• MAHA Action (Make America Healthy Again Action)
• The CPAC Foundation
• The National Health Federation
• The Health Freedom Defense Fund
• The Natural Products Association

These organizations represent millions of American consumers, practitioners, and businesses who collectively view the bill as a long-overdue step toward securing access to homeopathic medicine for future generations.

What This Means for Homeopathy Supporters

For supporters of homeopathic medicine, S.4692 is more than a piece of legislation — it is a federal affirmation that homeopathy occupies a unique and legitimate place in the American healthcare landscape. The bill recognizes a simple reality: homeopathic medicines have been safely used in the United States for nearly two centuries and continue to be relied upon by millions of consumers and licensed health practitioners today.

If enacted, the Homeopathic Drug Product Safety, Quality, and Transparency Act would:

• Protect continued consumer access to the homeopathic medicines families depend on.
• Provide regulatory certainty for manufacturers, retailers, and practitioners.
• Ensure appropriate safety and quality standards designed specifically for homeopathic products.
• Stop the misuse of the term “homeopathy” in mislabeled mainstream products.
• Restore the original 1938 framework’s recognition of homeopathy as a distinct category of medicine.

Current Status and Next Steps

S.4692 was introduced on June 4, 2026, read twice, and referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP). Its House companion, H.R. 7050, is currently before the House Committee on Energy and Commerce.

The Homeopathic Medicine PAC will continue to monitor the bill’s progress, advocate for its advancement, and provide our supporters with timely updates and opportunities to engage their elected representatives.

We encourage all Americans who value access to homeopathic medicine to contact their U.S. Senators and ask them to support S.4692, the Homeopathic Drug Product Safety, Quality, and Transparency Act.

Sources and Further Reading

• Bill page: S.4692 — 119th Congress (2025-2026)
• Cosponsors: Congress.gov cosponsor list
• Senator Lee’s press release (June 5, 2026): lee.senate.gov
• House companion bill: H.R. 7050 — Homeopathic Drug Product Safety, Quality, and Transparency Act

The Homeopathic Medicine PAC is committed to protecting and advancing Americans’ access to safe, effective homeopathic medicine through policy advocacy, education, and civic engagement.

April 21, 2026 — The momentum behind the Homeopathic Drug Product Safety, Quality, and Transparency Act continues to grow. Representative Burgess Owens (R-UT) has become the latest member of Congress to sign on as a co-sponsor of HR 7050, joining a growing bipartisan coalition committed to bringing clarity and consumer protection to the homeopathic drug products market.

About Representative Owens

Representative Burgess Owens represents Utah’s 4th Congressional District and brings a distinctive background to Congress — a former NFL safety turned business executive and advocate for economic opportunity, education reform, and veterans’ support. His decision to co-sponsor HR 7050 adds further Utah representation to the bill, alongside fellow co-sponsor Representative Dr. Mike Kennedy (R-UT), who joined at the bill’s introduction in January.

Growing Support for the Bill

HR 7050 was introduced on January 14, 2026 by sponsor Representative Pete Sessions (R-TX) and has steadily expanded its base of support in the months since. The bill now counts three co-sponsors:

• Representative Jonathan Jackson (D-IL)
• Representative Dr. Mike Kennedy (R-UT)
• Representative Burgess Owens (R-UT) (joined April 21, 2026)

The bill has been referred to the House Committee on Energy and Commerce, where it awaits further action.

Why This Matters

Each new co-sponsor signals expanding congressional recognition that homeopathic products — used by millions of Americans — deserve a clear, dedicated regulatory pathway. Representative Owens’s support reinforces Utah’s strong presence on this issue and underscores that this is not a fringe concern but one with real legislative traction across districts and political backgrounds.

With three co-sponsors now on record and bipartisan backing from the start, HR 7050 continues building the foundation it needs to advance through committee and onto the House floor.

January 14, 2026 marked a landmark moment for homeopathic medicine in the United States, as the Homeopathic Drug Product Safety, Quality, and Transparency Act (HR 7050) was formally introduced into the House of Representatives.

A Bipartisan Effort

The bill was sponsored by Representative Pete Sessions (R-TX) and drew meaningful bipartisan support from its earliest days. Co-sponsors include Representative Jonathan Jackson (D-IL) and Representative Dr. Mike Kennedy (R-UT) — a Republican, a Democrat, and a physician among them — reflecting broad, cross-aisle interest in establishing clear standards for homeopathic drug products.

What the Bill Addresses

HR 7050 focuses on three core pillars for homeopathic drug products in the United States:

• Safety — Establishing standards to ensure homeopathic products meet consistent safety requirements
• Quality — Setting benchmarks for the manufacturing and composition of homeopathic drug products
• Transparency — Promoting clearer labeling and disclosure so consumers and healthcare providers have the information they need

Why It Matters

Homeopathic products occupy a unique and often debated space in American healthcare. For decades, the regulatory landscape governing these products has lacked the clarity found in conventional pharmaceutical oversight. The introduction of HR 7050 represents one of the most significant legislative efforts in recent history to bring formal federal standards to this sector.

The bill’s bipartisan sponsorship signals that support for addressing homeopathic product oversight spans the political spectrum — from conservative lawmakers to progressive voices and medical professionals alike.

Looking Ahead

With its introduction on January 14, 2026, HR 7050 now begins its journey through the legislative process. Advocates for homeopathic medicine, patient safety groups, and healthcare professionals will be watching closely as the bill moves through committee review and potential floor consideration.